EPH133 Real-World Effectiveness of Osimertinib in Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutation: Systematic Review and Meta-Analysis

A. Almutairi, N. Alkhatib, M. Maghaireh, S. Halloush, O. Rashdan, A. Manasrah, I. Abraham, A. Almaaytah, H. Abumansour, M. Saleh, A. Khassawaneh

Value in Health（2023）

Cited 0|Views5

No score

Abstract

Osimertinib has been lunched in 2018 as an innovative tyrosine kinase inhibitor in the treatment of non-small cell lung cancer (NSCLC) that targets T790M mutations. The assessment of real-world effectiveness of osimertinib is lacking. This study aims to evaluate the real-world effectiveness of osimertinib in NSCLC.

Translated text

Key words

egfr mutation,osimertinib,cell lung cancer,real-world,non-small,meta-analysis

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined